These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 12697644

  • 21. Mechanism of action of and resistance to quinolones.
    Fàbrega A, Madurga S, Giralt E, Vila J.
    Microb Biotechnol; 2009 Jan; 2(1):40-61. PubMed ID: 21261881
    [Abstract] [Full Text] [Related]

  • 22. [Quinolone].
    Sato K, Tanaka M.
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():227-33. PubMed ID: 12717976
    [No Abstract] [Full Text] [Related]

  • 23. Characterization of the molecular mechanisms of quinolone resistance in Yersinia enterocolitica O:3 clinical isolates.
    Capilla S, Ruiz J, Goñi P, Castillo J, Rubio MC, Jiménez de Anta MT, Gómez-Lus R, Vila J.
    J Antimicrob Chemother; 2004 Jun; 53(6):1068-71. PubMed ID: 15117921
    [Abstract] [Full Text] [Related]

  • 24. [Mechanisms of bacterial resistance to quinolones].
    Taléns-Visconti R, Garrigues TM, Cantón E.
    Rev Esp Quimioter; 2002 Mar; 15(1):25-31. PubMed ID: 12582434
    [Abstract] [Full Text] [Related]

  • 25. [Investigating the fluoroquinolone molecular resistant mechanism of Stenotrophomonas maltophilia].
    Tao CM, Lü XJ, Li P.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):266-9. PubMed ID: 16608091
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [The molecular physiological and genetic mechanisms underlying the superb efficacy of quinolones].
    Long QX, He Y, Xie JP.
    Yao Xue Xue Bao; 2012 Aug; 47(8):969-77. PubMed ID: 23162891
    [Abstract] [Full Text] [Related]

  • 31. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones.
    Sanders CC.
    Clin Infect Dis; 2001 Mar 15; 32 Suppl 1():S1-8. PubMed ID: 11249822
    [Abstract] [Full Text] [Related]

  • 32. Mechanisms of quinolone action and resistance: where do we stand?
    Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G.
    J Med Microbiol; 2017 May 15; 66(5):551-559. PubMed ID: 28504927
    [Abstract] [Full Text] [Related]

  • 33. [Bacterial resistance to antiseptics and disinfectants].
    Alp S.
    Mikrobiyol Bul; 2007 Jan 15; 41(1):155-61. PubMed ID: 17427567
    [Abstract] [Full Text] [Related]

  • 34. Synthesis and antibacterial activity of a novel series of DNA gyrase inhibitors: 5-[(E)-2-arylvinyl]pyrazoles.
    Tanitame A, Oyamada Y, Ofuji K, Terauchi H, Kawasaki M, Wachi M, Yamagishi J.
    Bioorg Med Chem Lett; 2005 Oct 01; 15(19):4299-303. PubMed ID: 16087337
    [Abstract] [Full Text] [Related]

  • 35. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C, Hogan T, White P, Tapsall J.
    Pathology; 2004 Apr 01; 36(2):166-9. PubMed ID: 15203753
    [Abstract] [Full Text] [Related]

  • 36. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K, Zhao X.
    Microbiol Mol Biol Rev; 1997 Sep 01; 61(3):377-92. PubMed ID: 9293187
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial susceptibility and molecular determinants of quinolone resistance in Neisseria gonorrhoeae isolates from Shanghai.
    Yang Y, Liao M, Gu WM, Bell K, Wu L, Eng NF, Zhang CG, Chen Y, Jolly AM, Dillon JA.
    J Antimicrob Chemother; 2006 Oct 01; 58(4):868-72. PubMed ID: 16880174
    [Abstract] [Full Text] [Related]

  • 38. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents.
    Mitscher LA.
    Chem Rev; 2005 Feb 01; 105(2):559-92. PubMed ID: 15700957
    [No Abstract] [Full Text] [Related]

  • 39. Plasmid-mediated quinolone resistance.
    Martínez-Martínez L, Eliecer Cano M, Manuel Rodríguez-Martínez J, Calvo J, Pascual A.
    Expert Rev Anti Infect Ther; 2008 Oct 01; 6(5):685-711. PubMed ID: 18847406
    [Abstract] [Full Text] [Related]

  • 40. [Bacterial type II topoisomerases as targets for antibacterial drugs].
    Pietrusiński M, Staczek P.
    Postepy Biochem; 2006 Oct 01; 52(3):271-82. PubMed ID: 17201062
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.